Pharma Industry Braces For Biennial Price Cuts In Taiwan
This article was originally published in PharmAsia News
Although Taiwan’s most recent cuts will have less impact than last go around, industry will still feel the pinch.
You may also be interested in...
HONG KONG - Taiwan's government plans to carry forward with a biannual round of cuts to drug prices despite intense opposition from the pharmaceutical industry
Regulators in Southeast Asia are working to tighten bribery and corruption enforcement as part of a broader push ahead of an Association of Southeast Asian Nations trade pact in 2015 for greater transparency in pharmaceuticals.
The first commercial implant for St. Jude’s Allure Quadra in Hong Kong is a sign for optimism for its pacemaker business after last year’s disappointments in Japan.